222 is a unique platform that facilitates chance social encounters, allowing members to meet new people, discover their cities, and deepen relationships through curated experiences. Unlike traditional dating or networking apps, 222 emphasizes real-life interactions without profiles, DMs, or scrolling, focusing on genuine connections in public group settings. The company has evolved from hosting backyard dinners to helping thousands of members engage in meaningful social experiences each week, positioning itself as a refreshing alternative to virtual distractions.

Rethinking the science of prediction.

Accordance is Frontier AI for tax, audit, and CPA teams. We're on a mission to unlock the true value of unstructured financial data to make practicing tax easier and more gratifying.

Afterhour is the social platform for modern investors – it's like ROBINHOOD and DISCORD had a baby. Our mission is to increase wealth through financial entertainment, transparency, and access. Founded in 2022, we have raised $X millions in seed funding from top-tier VCs to become the new face of finance.

Blockchain is eating the world of financial services and payments. Over the next 10 years, money, payments, and banking will move to blockchain-based networks. At Agora, we’re accelerating this transition. We’re building a global financial ecosystem enabled by this technology. One that advances financial access and opportunity, and reduces costs around sending and receiving money. We started with our flagship stablecoin, AUSD, and are building across the infrastructure and application layers to change the way the world transfers value.

Aidoc is a pioneering force in clinical AI. We focus on aiding and empowering healthcare teams to optimize patient outcomes, which results in improved economic value and clinical outcomes. Our clinically proven AI solutions eliminate silos, increase efficiencies, and improve outcomes by delivering critical information when and where care teams need it, leading to immediate collective action. Built on Aidoc’s exclusive AIOS™, we analyze and aggregate medical data to enable care teams to operationalize the unexpected and work seamlessly with a continued focus on the patient. Aidoc AI is always on, running in the background to change the foreground. For safety information on Aidoc’s products, please visit our safety and compliance page on our website.

AIM delivers maximum safety and productivity across mining, large scale construction, and defense operations. AIM’s platform provides a rugged plug-and-play solution for a wide range of heavy equipment fleets in the field today. We take customers from their current mode of operation to autonomous operation with a rigorous 3-step process. AIM’s platform enables mining equipment to run continuously at peak performance across weather conditions—thereby unlocking operational and CapEx value across fuel savings, duty cycle, fleet availability, optimal AI site planning and more. This results in maximally safe zero-entry sites, where all ground staff is out of harm’s way. AIM technology has been built by world-class engineers who developed autonomous products at Waymo, SpaceX, Google & Tesla. We bring deep expertise in autonomy, robotics, hardware, and advanced AI deployed at scale.

AirSlate is building what's next for workflows. Read all the latest news and exciting updates here.

Evitamos os altos reajustes com planos de saúde ao mesmo tempo em que crescemos a saúde das pessoas, sem a necessidade de troca de operadora/plano de saúde. Atuamos com ciência de dados, assim conseguimos realizar um atendimento primário e, se necessário, realizamos um direcionamento inteligente, levando os colaboradores de nossos parceiros para os prestadores (médicos, hospitais, clínicas, laboratórios) com a melhor qualidade de atendimento e menos custo. Além do direcionamento inteligente, os colaboradores de nossos parceiros entram no cuidado integral de nossa equipe médica, onde existe um acompanhamento contínuo. Nossos médicos, além de realizarem um acompanhamento contínuo, aplicam a metodologia Lifestyle Medicine, auxiliando no estilo de vida saudável, reduzindo as chances do desenvolvimento de doenças crônicas. Trabalhamos para reduzir custos ao mesmo tempo em que crescemos a saúde das pessoas!

Allego is the leading provider of modern revenue enablement software. GO, Allego’s modern revenue enablement platform, brings together sales, enablement, and marketing teams to deliver the experience B2B buyers are looking for — in a single, comprehensive platform. With its patented technology, the GO platform ensures revenue teams curate the right content, ready sales teams to win with confidence, and engage with buyers in the right way at the right time for faster sales cycles and greater revenue. Allego is the trusted choice for one quarter of Dow Jones Industrial Average companies, 5 of the 15 largest U.S. banks, 4 of the 8 largest insurance providers, 4 of the 5 largest global medical device companies, 6 of the 10 largest wealth management firms, 5 of the 5 largest asset management companies, and many other global enterprises. Learn more about revenue enablement that wins sellers and buyers at allego.com.

Almanac is how the fastest remote teams work on the Internet, with more structure, more transparency, and fewer meetings. It's the only async all-in-one platform where you can write, approve, organize, and track docs. Whether you're looking to document knowledge, collaborate with teammates, or manage projects, you can do it all on Almanac.

Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.